Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd.  This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:   touchONCOLOGY: https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/ touchRESPIRATORY: https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/